Chimeric Antigen News Today

09.04.2024 - - Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technology for targeting hematologic and solid tumor ... Seite 1

The Centers for Medicare & Medicaid Services (CMS) released the final calendar year (CY) 2024 Physician Fee Schedule (PFS) on Nov. 2, 2023.

Appointment of industry veterans, Dr. Hans-Peter Gerber, PhD, as Chairman and Dr. Bernd Eschgfäller, PhD, as independent Board member.Strengthens T-CURX’s Board to accelerate the commercialization of its proprietary CAR-T technologies and CAR-T pipeline programs.WÜRZBURG, Germany, August 28, 2023 / B3C new...

Piscataway, NJ (PRWEB) July 19, 2023 -- GenScript Biotech Corporation, a world-leading biotech company offering comprehensive solutions in gene, peptide,

BOSTON, MA, USA and BERLIN, Germany, May 17, 2023 / B3C newswire / -- ProBioGen today announced the launch of their lentivirus (LV) packaging cell line Lenti.RiGHT™ as a new platinum standard for LV production at this year's PEGS Boston 2023. The lentivirus production platform is based on HEK293 packaging cells...

/PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing...

WÜRZBURG, Germany, December 15, 2022 / B3C newswire / -- T-CURX GmbH (T-CURX) today announces the appointment of Thomas (Tom) Loeser as the new CFO of the company and the attendance of the JPM 41st Annual Healthcare Conference 2023 in San Francisco from Jan 9-12, 2023.Tom has served for more than 20 years as CFO of...

T-CURX announces the appointment of Tom Loeser as the new CFO of the company and the attendance of the JPM 41st Annual Healthcare Conference 2023 in San Francisco from Jan 9-12, 2023.

As severe shortages of fludarabine drag on and prices soar, transplant centers are struggling to cope. The drug is an essential component of stem-cell transplants for some blood cancers.

Findings on the mechanism of action from the BOXR CAR-T platform indicate improved metabolic function and preservation of early memory subsets of T cells SOTIO anticipates initiating first-in-human DUET-01 trial for lead CAR-T cell therapy candidate, BOXR1030, in coming monthsPhase 2 AURELIO-04 combination study of...